We are extremely happy to inform you that our Fesoterodine 4mg and 8mg sustained release (SR) tablets have passed the pivotal bioequivalence studies and the dossier will be ready for filling in June 2021.
Feel free to contact the Intas B2B team in case of interest in these MA´s or for further information.
